Every-Other-Day Feeding Prevents the Loss of Parvalbumin-Expressing Neurons in the Cerebral Cortex of Female 5xFAD Mice Jelena Ciric, Milka Perovic, Nikola Milovanovic, Suryanarayana Polaka, Irena Jovanovic Macura, Natasa Nestorovic, Vesna Tesic Molecular Neurobiology, 2026 The present study demonstrates the effects of an every-other-day (EOD) feeding regimen on parvalbumin (PV)-expressing interneurons in the cortex of 5xFAD mice, a well-established animal model of Alzheimer’s disease (AD). Female 5xFAD mice and their non-transgenic littermates were maintained on either an ad libitum (AL) or EOD feeding regimen throughout the presymptomatic phase of the pathology, with comprehensive immunohistochemical and Western blot analyses performed in 6-month-old animals. In AL-fed 5xFAD mice, significant reductions in PV-expressing interneurons were observed in the retrosplenial granular, parietal, and somatosensory cortices compared to non-transgenic controls, supporting their established vulnerability in AD pathology. This neuronal loss was accompanied by a decline in the levels of brain-derived neurotrophic factor (BDNF), a key neurotrophin essential for cell survival and synaptic plasticity. Remarkably, four months of EOD feeding prevented the Aβ-induced loss of PV interneurons and increased the total protein levels of the BDNF receptor TrkB, suggesting enhanced neurotrophic signaling. However, the benefits of EOD feeding were not uniform across all molecular markers, with EOD-fed 5xFAD mice retaining deficits in phosphorylated CaMKII and CREB-binding protein (CBP) and biochemical analysis of plasma indicating metabolic stress-related effects. Together, these results align with the GABAergic hypofunction hypothesis in AD, underscoring the importance of PV interneuron plasticity in neurodegeneration and cognitive decline. They also suggest that dietary strategies like EOD feeding may offer partial neuroprotective effects during early AD progression, however, complex stress-related impacts of EOD in the modulation of PV neuron function remain to be elucidated. Future studies are also warranted to more carefully explore the long-term translational potential of dietary interventions and the interplay between metabolic stress and amyloid pathology, in order to identify novel therapeutic targets across distinct neuronal populations.
Roadmap for Commercial Nanomedicine Development: Integrating Quality by Design Principles with Pharmaceutical Nanotechnology Rahul Maheshwari, Devesh Kapoor, Suryanarayana Polaka, Sankha Bhattacharya, Bhupendra Prajapati Molecular Pharmaceutics, 2025 Integrating Quality by Design (QbD) principles into nanomedicine development marks a paradigm shift from traditional empirical approaches to more systematic risk-based strategies. This review explores the application of QbD in pharmaceutical nanotechnology, focusing on nanoliposomes as a drug and gene delivery model. We examine various QbD models, including factorial, Plackett-Burman, Box-Behnken, and Taguchi experimental designs, alongside response optimization methods such as artificial neural networks (ANNs), mathematical optimization, and overlay plots. A comparison of QbD versus conventional optimization techniques highlights the potential of QbD to improve process efficiency, reduce variability, and enhance product quality. Case studies demonstrate the practical application of QbD in developing nanoliposomal formulations for treating complex diseases such as diabetes, cardiovascular diseases, rheumatoid arthritis, and CNS disorders. Furthermore, we discuss the regulatory and industrial considerations for commercializing nanoliposomal-based therapies, emphasizing FDA guidelines and the challenges associated with scaling up nanomedicine production. Different from available reviews in the field, this review uniquely integrates diverse QbD models with nanoliposome development, offering practical insights. Also, we aimed to bridge laboratory research with industrial scale-up and regulatory requirements. Overall, the present review critically contrasts QbD with conventional methods, using real case studies to highlight its superiority in ensuring product quality, consistency, and efficiency.
Harnessing Exercise-Like Benefits of Protonation prone Liposomal Resveratrol in Differentiated Fat Cells: A Proof-of-Concept Study Nupur Vasdev, Tanisha Gupta, Anoothi Bain, Dnyaneshwar Kalyane, Suryanarayana Polaka, Rakesh Kumar Tekade AAPS Pharmscitech, 2025 Obesity is a significant health issue resulting from a sedentary lifestyle and is linked to numerous other serious conditions, including cancer, diabetes, and cardiovascular diseases. Consequently, resveratrol (RES) is gaining attention as an emerging therapeutic agent due to its exercise-like effects. However, RES's instability and low aqueous solubility have limited its applications. This research report focuses on the loading, solubilization, and sustained delivery of RES using a dendrimer complex loaded liposomal formulation. The safety and efficacy of formulation was studied by performing various assays. The DEN-RES complex loaded liposomes were optimized using a Quality by Design (QbD) approach whereas particle size, PDI and zeta potential were found to be 159.29 ± 0.58 nm, 0.206 ± 0.008, and -7.2 ± 0.14 mV, which followed first-order release kinetics for sustained RES release. The mRNA levels of the SIRT1 and AMPK genes were found to be upregulated by more than two folds, whereas the LIPO-DEN-RES downregulated the mRNA expression of PPARγ in adipocytes. Therefore, the modulation of mRNA levels detected in 3T3-L1 cells post-treatment with the LIPO-DEN-RES validates the formulation's potential in addressing obesity.
Opto-Laser-Responsive Smart NanoGel with Mild Hyperthermia, Vascularization, and Anti-Inflammatory Potential for Boosting Hard-to-Heal Wounds in a Diabetic Mice Model Bhakti Pawar, Shivam Otavi, Amrita Singh, Suryanarayana Polaka, Nupur Vasdev, Tanisha Gupta, Rakesh K. Tekade Molecular Pharmaceutics, 2025 It is well known that impaired wound healing associated with diabetes mellitus has led to a challenging problem as well as a global economic healthcare burden. Conventional wound care therapies like films, gauze, and bandages fail to cure diabetic wounds, thereby demanding a synergistic and promising wound care therapy. This investigation aimed to develop a novel, greener synthesis of a laser-responsive silver nanocolloid (LR-SNC) prepared using hyaluronic acid as a bioreductant. The prepared LR-SNC was embedded into a stimuli-responsive in situ gel (LR-SNC-in situ gel) for easy application to the wound region. The physicochemical characterization of LR-SNC revealed a nanometric hydrodynamic particle size of 25.59 ± 0.72 nm with an -31.8 ± 0.7 mV surface ζ-potential. The photothermal conversion efficiency of LR-SNC was observed up to 62.9 ± 0.1 °C. In vitro evaluation of LR-SNC with and without NIR laser irradiation exhibited >70% cell viability, confirming its cytocompatibility for human keratinocyte cells. The in vitro scratch assay showed significant wound closure of 75.50 ± 0.02%. Further, the addition of cytocompatible LR-SNC into an in situ gel followed by laser irradiation resulted in substantial in vivo wound closure (86.69 ± 2.48%) in a diabetic wound-bearing mouse. Histological evaluation demonstrated salient features of the healed wounds, such as increased neovascularization, collagen density, migration of keratinocytes, as well as growth of hair follicles. Additionally, the findings showed a decrease in the levels of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) and enhanced angiogenesis gene expression (VEGF and CD31), thereby healing the diabetic wound efficiently. The present study confirmed the potential role of silver nanocolloids followed by laser irradiation in treating diabetic wound mouse models.
Elucidation of processing parameters for the reverse engineering of tablets Devendra Choudhary, Dnyaneshwar Kalyane, Suryanarayana Polaka, Tanisha Gupta, Rakesh Kumar Tekade Rsc Pharmaceutics, 2024 Reverse engineering can assist in decoding the formula and manufacturing parameters employed in innovator formulations.
Nanotechnology and Safety Pharmacology Suryanarayana Polaka, Rakesh K. Tekade, Narendra K. Jain Drug Discovery and Evaluation Safety and Pharmacokinetic Assays Volume 1 3 Third Edition, 2024
Connecting link between pesticides and Parkinson's disease Suryanarayana Polaka, Sivarupa Raji, Aditya Singh, Pratik Katare, Rakesh Kumar Tekade Public Health and Toxicology Issues in Drug Research Volume 2 Toxicity and Toxicodynamics, 2024
Exosomes as mediators of chemical-induced toxicity Suryanarayana Polaka, Muktika Tekade, Nupur Vasdev, Tanisha Gupta, Bhakti Pawar, Maliheh Safavi, Rakesh Kumar Tekade Essentials of Pharmatoxicology in Drug Research Toxicity and Toxicodynamics Volume 1, 2023
Molecular mechanisms of the chemopreventive role of dietary phytochemicals Suryanarayana Polaka, Nupur Vasdev, Lakshmi Vineela Nalla, Sivarupa Raji, Muktika Tekade, Nagendra Singh Chauhan, Satyajit D. Sarker, Rakesh Kumar Tekade Essentials of Pharmatoxicology in Drug Research Toxicity and Toxicodynamics Volume 1, 2023
Drug-induced nephrotoxicity and its biomarkers Suryanarayana Polaka, Lakshmi Vineela Nalla, Rana Dhwani Kalpeshkumar, Paritala Sree Teja, Anand More, Muktika Tekade, Dinesh Kumar Chellappan, Rakesh Kumar Tekade Essentials of Pharmatoxicology in Drug Research Toxicity and Toxicodynamics Volume 1, 2023
Cells and tissue-based models as a rational substitute in toxicity testing Mamata Panchal, Vinayak Pawar, Mahi Mhatre, Shweta Ingole, Suryanarayana Polaka, Muktika Tekade, Kuldeep Rajpoot, Rakesh Kumar Tekade Essentials of Pharmatoxicology in Drug Research Toxicity and Toxicodynamics Volume 1, 2023
Molecular biology of apoptotic, necrotic, and necroptotic cell death Suryanarayana Polaka, Hari Priya Koppisetti, Rutuja Satvase, Aparna Lakshmi Manchikalapudi, Muktika Tekade, Mukesh Chandra Sharma, Rakesh Kumar Tekade Pharmacokinetics and Toxicokinetic Considerations Vol II, 2022
Toxicokinetic and toxicodynamic considerations in drug research Kuldeep Rajpoot, Pratik Katare, Muktika Tekade, Mukesh Chandra Sharma, Suryanarayana Polaka, Pinaki Sengupta, Rakesh Kumar Tekade Pharmacokinetics and Toxicokinetic Considerations Vol II, 2022
Clinical importance of herb-drug interaction Suryanarayana Polaka, Sayali Chaudhari, Muktika Tekade, Mukesh Chandra Sharma, Neelesh Malviya, Sapna Malviya, Rakesh Kumar Tekade Pharmacokinetics and Toxicokinetic Considerations Vol II, 2022
Pharmaceutical excipients: Special focus on adverse interactions Suryanarayana Polaka, Shyam Sudhakar Gomte, Vikas Pandey, Jai Divya Tella, Muktika Tekade, Mukesh Chandra Sharma, Nagashekhara Molugulu, Rakesh Kumar Tekade Pharmacokinetics and Toxicokinetic Considerations Vol II, 2022
Factors affecting the pharmacokinetics of the liposomal drugs Suryanarayana Polaka, Kiran Katrajkar, D.V. Siva Reddy, Havish Shukla, Basel Arafat, Rakesh Kumar Tekade Biopharmaceutics and Pharmacokinetics Considerations Volume 1 in Advances in Pharmaceutical Product Development and Research, 2021
Every-Other-Day Feeding Prevents the Loss of Parvalbumin-Expressing Neurons in the Cerebral Cortex of Female 5xFAD Mice J Ciric, M Perovic, N Milovanovic, S Polaka, I Jovanovic Macura, ... Molecular Neurobiology 63 (1), 195 , 2026 2026 Citations: 1
Emerging technologies in modifying inulin properties for sustainable and innovative product development S Arumilli, SSD Manyam, P Samathoti, SM Latha, K Anitha, S Polaka Comprehensive Guide to Inulin, 397-416 , 2026 2026
Adipose homing peptide-engineered Anti-miR lipodendriplex for exercise mimicry and combating obesity in high-fat diet-induced obese mice N Vasdev, T Gupta, N Desai, S Polaka, R Sahu, S Kaur, P Gondaliya, ... Journal of Drug Delivery Science and Technology, 107768 , 2025 2025 Citations: 2
Roadmap for Commercial Nanomedicine Development: Integrating Quality by Design Principles with Pharmaceutical Nanotechnology R Maheshwari, D Kapoor, S Polaka, S Bhattacharya, B Prajapati Molecular Pharmaceutics 22 (8), 4337-4372 , 2025 2025 Citations: 20
Harnessing Exercise-Like Benefits of Protonation prone Liposomal Resveratrol in Differentiated Fat Cells: A Proof-of-Concept Study N Vasdev, T Gupta, A Bain, D Kalyane, S Polaka, RK Tekade AAPS PharmSciTech 26 (4), 98 , 2025 2025 Citations: 4
Opto-Laser-Responsive Smart NanoGel with Mild Hyperthermia, Vascularization, and Anti-Inflammatory Potential for Boosting Hard-to-Heal Wounds in a Diabetic Mice Model B Pawar, S Otavi, A Singh, S Polaka, N Vasdev, T Gupta, RK Tekade Molecular Pharmaceutics 22 (2), 1079-1097 , 2025 2025 Citations: 1
Development and biological evaluation of smart powder bandage for wound healing and dressing applications S Polaka, B Pawar, N Vasdev, RK Tekade International Journal of Biological Macromolecules 258, 129044 , 2024 2024 Citations: 21
Elucidation of processing parameters for the reverse engineering of tablets D Choudhary, D Kalyane, S Polaka, T Gupta, RK Tekade RSC Pharmaceutics 1 (2), 333-343 , 2024 2024 Citations: 3
Connecting link between pesticides and Parkinson's disease S Polaka, S Raji, A Singh, P Katare, RK Tekade Public Health and Toxicology Issues in Drug Research, 735-754 , 2024 2024 Citations: 7
Insect repellents as an environmental chemical toxicant to human health P Katare, S Polaka, LV Nalla, V Makwana, RK Tekade Public Health and Toxicology Issues in Drug Research, 523-554 , 2024 2024 Citations: 5
Cancer Cell‐Specific and Laser‐Activatable NanoSeeds for Targeted Photothermal Ablation of Triple‐Negative Breast Cancer D Kalyane, S Polaka, N Vasdev, RK Tekade Photochemistry and Photobiology 99 (4), 1157-1171 , 2023 2023 Citations: 12
Development and evaluation of silver nanomix as a Next-Generation tool for wound healing and dressing applications S Polaka, RK Tekade ACS Applied Bio Materials 6 (5), 1832-1848 , 2023 2023 Citations: 15
Nanotechnology and Safety Pharmacology S Polaka, RK Tekade, NK Jain Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays, 1-29 , 2023 2023 Citations: 1
Exosomes as mediators of chemical-induced toxicity S Polaka, M Tekade, N Vasdev, T Gupta, B Pawar, M Safavi, RK Tekade Essentials of Pharmatoxicology in Drug Research, 97-112 , 2023 2023
Drug-induced nephrotoxicity and its biomarkers S Polaka, LV Nalla, RD Kalpeshkumar, PS Teja, A More, M Tekade, ... Essentials of Pharmatoxicology in Drug Research, 289-316 , 2023 2023 Citations: 2
Cells and tissue-based models as a rational substitute in toxicity testing M Panchal, V Pawar, M Mhatre, S Ingole, S Polaka, M Tekade, K Rajpoot, ... Essentials of Pharmatoxicology in Drug Research, 625-672 , 2023 2023 Citations: 3
Molecular mechanisms of the chemopreventive role of dietary phytochemicals S Polaka, N Vasdev, LV Nalla, S Raji, M Tekade, NS Chauhan, SD Sarker, ... Essentials of Pharmatoxicology in Drug Research, 507-529 , 2023 2023
Current progress in preservative-free topical ophthalmic formulations N Vasdev, N Chaudhari, S Polaka, K Rajpoot, P Gondaliya, AA Sayyed, ... Journal of Drug Delivery Science and Technology 79, 103996 , 2023 2023 Citations: 9
CD44-receptor targeted gold-doxorubicin nanocomposite for pulsatile chemo-photothermal therapy of triple-negative breast cancer cells D Kalyane, S Polaka, N Vasdev, RK Tekade Pharmaceutics 14 (12), 2734 , 2022 2022 Citations: 16
Reactive oxygen nano-generators for cancer therapy D Kalyane, D Choudhary, S Polaka, H Goykar, T Karanwad, K Rajpoot, ... Progress in Materials Science 130, 100974 , 2022 2022 Citations: 59
MOST CITED SCHOLAR PUBLICATIONS
Emerging ROS-modulating technologies for augmentation of the wound healing process S Polaka, P Katare, B Pawar, N Vasdev, T Gupta, K Rajpoot, P Sengupta, ... ACS omega 7 (35), 30657-30672 , 2022 2022 Citations: 149
Artificial intelligence in the pharmaceutical sector: current scene and future prospect D Kalyane, G Sanap, D Paul, S Shenoy, N Anup, S Polaka, V Tambe, ... The future of pharmaceutical product development and research, 73-107 , 2020 2020 Citations: 78
Role of omega-3 fatty acids and butter oil in targeting delivery of donepezil hydrochloride microemulsion to brain via the intranasal route: a comparative study D Khunt, M Shrivas, S Polaka, P Gondaliya, M Misra AAPS PharmSciTech 21 (2), 45 , 2020 2020 Citations: 68
Reactive oxygen nano-generators for cancer therapy D Kalyane, D Choudhary, S Polaka, H Goykar, T Karanwad, K Rajpoot, ... Progress in Materials Science 130, 100974 , 2022 2022 Citations: 59
Importance of toxicity testing in drug discovery and research R Gupta, S Polaka, K Rajpoot, M Tekade, MC Sharma, RK Tekade Pharmacokinetics and toxicokinetic considerations, 117-144 , 2022 2022 Citations: 52
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia P Kochar, K Nayak, S Thakkar, S Polaka, D Khunt, M Misra Cutaneous and Ocular Toxicology 39 (1), 43-53 , 2020 2020 Citations: 48
Reinforced electrospun nanofiber composites for drug delivery applications N Anup, T Chavan, S Chavan, S Polaka, D Kalyane, SN Abed, ... Journal of Biomedical Materials Research Part A 109 (10), 2036-2064 , 2021 2021 Citations: 42
Pharmacokinetics and toxicokinetic considerations R Gupta, S Polaka, K Rajpoot, M Tekade, MC Sharma, RK Tekade Pharmaceutical Product Development and Research, 27-50 , 2022 2022 Citations: 40
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis A Gadeval, S Chaudhari, SP Bollampally, S Polaka, D Kalyane, ... Drug Discovery Today 26 (10), 2315-2328 , 2021 2021 Citations: 40
Update on compatibility assessment of empagliflozin with the selected pharmaceutical excipients employed in solid dosage forms by thermal, spectroscopic and chromatographic … P Niguram, SN Polaka, R Rathod, K Kalia, AS Kate Drug Development and Industrial Pharmacy 46 (2), 209-218 , 2020 2020 Citations: 26
Development and biological evaluation of smart powder bandage for wound healing and dressing applications S Polaka, B Pawar, N Vasdev, RK Tekade International Journal of Biological Macromolecules 258, 129044 , 2024 2024 Citations: 21
Drug–drug interactions and their implications on the pharmacokinetics of the drugs S Polaka, HP Koppisetti, M Tekade, MC Sharma, P Sengupta, RK Tekade Pharmacokinetics and toxicokinetic considerations, 291-322 , 2022 2022 Citations: 21
Comparative evaluation of fish oil and butter oil in modulating delivery of galantamine hydrobromide to brain via intranasal route: pharmacokinetic and oxidative stress studies A Katdare, D Khunt, S Thakkar, SN Polaka, M Misra Drug delivery and translational research 10 (4), 1136-1146 , 2020 2020 Citations: 21
Biodistribution and amyloid beta induced cell line toxicity study of intranasal Rivastigmine microemulsion enriched with Fish Oil and Butter oil D Khunt, S Polaka, M Shrivas, M Misra Journal of Drug Delivery Science and Technology 57, 101661 , 2020 2020 Citations: 21
Roadmap for Commercial Nanomedicine Development: Integrating Quality by Design Principles with Pharmaceutical Nanotechnology R Maheshwari, D Kapoor, S Polaka, S Bhattacharya, B Prajapati Molecular Pharmaceutics 22 (8), 4337-4372 , 2025 2025 Citations: 20
Engineering immunity via skin-directed drug delivery devices S Polaka, V Makwana, N Vasdev, A Sheth, K Rajpoot, P Sengupta, ... Journal of Controlled Release 345, 385-404 , 2022 2022 Citations: 17
CD44-receptor targeted gold-doxorubicin nanocomposite for pulsatile chemo-photothermal therapy of triple-negative breast cancer cells D Kalyane, S Polaka, N Vasdev, RK Tekade Pharmaceutics 14 (12), 2734 , 2022 2022 Citations: 16
Biosimilars accessible in the market for the treatment of cancer AS Ditani, PP Mallick, N Anup, V Tambe, S Polaka, P Sengupta, ... Journal of Controlled Release 336, 112-129 , 2021 2021 Citations: 16
Development and evaluation of silver nanomix as a Next-Generation tool for wound healing and dressing applications S Polaka, RK Tekade ACS Applied Bio Materials 6 (5), 1832-1848 , 2023 2023 Citations: 15
‘Transfersome-embedded-gel’for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes P Todke, S Polaka, N Raval, P Gondaliya, V Tambe, R Maheshwari, ... Journal of Microencapsulation 39 (6), 495-511 , 2022 2022 Citations: 14